India’s first intranasal Covid vaccine by Bharat Biotech received approval from the Drug Controller General of India (DCGI) for primary immunization against the injection for people above the age of 18. It is India’s first nasal vaccine for COVID-19. The Union Minister of Health and Family Welfare Mansukh Mandaviya termed the vaccine a ‘Big Boost’ to India’s fight against COVID-19.
Bank Maha Pack includes Live Batches, Test Series, Video Lectures & eBooks
Bharat Biotech International Limited (BBIL), is a global leader in vaccine innovation and developer of vaccines for infectious diseases. The BBIL announced that the development of the Intranasal COVID vaccine (BBV154), has been approved for restricted use in an emergency. The iNCOVACC, is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein. This vaccine was evaluated in phases I, II, and III, clinical trials with successful results. The vaccine was formulated to allow Intranasal delivery through nasal drops. It is designed to be cost-effective in low and middle-income countries.
Let's Imagine you are walking a few minutes down a road and you just finding…
Every year in summer temperature soar across the India and millions of people are eagerly…
Every four years billions of football fans all around the world stick to sofas, stadium…
Football in Asia has continued to grow rapidly, with several Asian nations strengthening their position…
The National Statistics Office (NSO) under the Ministry of Statistics and Program Implementation (MoSPI) has…
India's Unified Payments Interface (UPI) has achieved the important milestone as it was launch in…